Affibody molecules (6-7 kDa) are a new class of small robust three-helical scaffold proteins. Radiolabeled subnanomolar anti-HER2 affibody Z HER2:342 was developed for imaging of HER2 expression in tumors and a clinical study has demonstrated that the 111 In-and 68 Ga-labeled affibody molecules can efficiently detect HER2 expressing metastases in breast cancer patients. However, significant renal accumulation of radioactivity after systemic injection of radiolabeled anti-HER2 affibody conjugate is observed. The aim of this study was to investigate the mechanism of renal reabsorption of anti-HER2 affibody at the molecular level. Renal accumulation of radiolabeled anti-HER2 affibody molecules was studied in murine model and in vitro using opossum derived proximal tubule cells (OK). It was found that kidney reabsorption of affibody was not driven by megalin/cubilin. Amino acids in the target-binding side of affibody were involved in binding to OK cells. On OK cells two types of receptors for anti-HER2 affibody were found: K D1 =0.8 nM, B max1 =71,500 and K D2 =9.2 nM, B max2 =367,000. The results of the present study indicate affibody and other scaffold-based targeting proteins with relatively low kidney uptake can be selected using in vitro studies with tubular kidney cells.
INTRODUCTION
Radionuclide molecular targeting is a promising method for detection, characterization and treatment of both localized and metastasized tumors. Several classes of radiolabeled proteins have been used for the delivery of radionuclides to tumors in vivo, utilizing the specific affinity of these agents for phenotypic alterations in malignant cells. In fact, tumor targeting with radiolabeled antibodies for detection of malignancy or for therapeutic purposes has been reported as early as the 1950's. 1 During the last decades, there was a general trend towards using smaller targeting proteins like antibody fragments, peptide hormones and scaffold proteins in order to overcome slow clearance of bulky antibodies. This strategy enables improved imaging with high contrast and reduction of the radiation dose to normal tissues during therapy. Nowadays, peptidebased radionuclide imaging and therapy plays a well established role in the management of patients with neuroendocrine tumors. 2 The use of somatostatin analogues for imaging and therapy of neuroendocrine tumors 3 and RGD (Arg-Gly-Asp) peptides to visualize tumorassociated angiogenesis 4 are some well known examples. Selectivity of these radionuclide loaded peptides to cancer cells, rapid penetration to the tumor tissue in combination with rapid clearance from normal tissues, designates them as very promising targeting agents.
Unfortunately, high kidney reabsorption after glomerular filtration was often a stumbling block for further development of many peptide-based agents as efficient radiolabeled targeting probes.
This tubular re-absorption of tracers smaller than the cut-off for glomerular filtration (~60 kDa) might potentially compromise reliable diagnostic accuracy in the retroperitoneal, periaortic and epigastric regions, especially with residualizing labels such as radiometals. 5 Moreover during radionuclide therapy, high accumulation of the radiotracer in the kidneys can be a limiting factor for successful delivery of appropriate radiation doses to tumors. For example, detoriation of renal functions is the dose limiting toxicity for treatment of neuroendocrine tumors with 90 Y-DOTATOC despite a number of kidney-protecting precautions (dose fractionation, co-injection of positively charged amino acids and pre-estimation of patient's risk factors). 6 It is known that megalin and cubilin, two endocytic receptors, expressed in proximal tubule, play a major role in normal reabsorption of proteins in kidneys. 7 It has been demonstrated that the scavenger receptor megalin, is the main mediator of renal accumulation of somatostatin analogues and other small peptides. 8, 9 Melis et al. showed that the reabsorbed somatostatin analogue, 111 In-DTPA-octreotide localized in the renal cortex. 10 Moreover, a profound decrease in radioactivity accumulation in the kidneys of megalin-deficient mice was observed for several radiolabeled small peptides, thus clearly indicating direct involvement of the megalin/cubilin system in the reabsorption process of these agents. 11 Accumulation of the radiotracer in the kidney by the megalin/cubilin system is a complex process. Megalin is a large multi-ligand receptor (517 kDa) with several domains, each of which might interact with different parts of the ligand. Different binding sites might be involved in the accumulation of different peptides. 12 Moreover, it was proposed that the differences in renal accumulation of radiopeptides may be related to the number of charged amino acids of a molecule. 13 These data indicate that the kidney reabsorption mechanism for each peptide-based radioactive probe could be individual and the optimal strategy for decreasing renal reabsorption could differ from one protein to another.
Affibody molecules (6-7 kDa) are a new class of small robust three-helical scaffold proteins, based on a modified B-domain of staphylococcal protein A. 14 Randomization of 13 amino acids on helices 1 and 2 provided a large library which enables molecular-display selection of highaffinity (ranging from low nanomolar to picomolar) binders to different proteins. 14, 15 Radiolabeled anti-HER2 affibody molecule Z HER2:342 and its derivatives have been evaluated preclinically for imaging of HER2 expression in tumors. 16 A clinical study has demonstrated that the 111 In-and 68 Ga-labeled affibody molecules can efficiently detect HER2 expressing metastases in breast cancer patients. 17 However, similar to other small proteins and peptides, efficient tumor targeting was associated with significant renal accumulation of the radioactivity. Fusion of Z HER2:342 with an albumin-binding domain (ABD) allows non-covalent binding of the conjugate to albumin in the circulation resulted in a dramatic decrease of renal uptake, 18 suggesting that the kidney uptake was associated with tubular re-absorption. At the same time the use of labeling methods yielding non-residualizing radiocatabolites caused a significant reduction of renal retention. [19] [20] [21] [22] [23] [24] [25] Better understanding of the fate of affibody molecules in the kidneys would open the way for the rational design of new affibody conjugates and/or could facilitate the development of substances that can effectively block kidney reabsorption. Therefore, here we studied the mechanism of kidney reabsorption of affibody molecules in detail both in vitro and in vivo. The opossum derived proximal tubule cell line (OK cells) was selected as an in vitro model for this study. In these cells the expression of scavenger receptors, transporters and kidney ion channels are preserved. [26] [27] [28] labeled with indium-111 via site-specifically conjugated maleimido derivative of DOTA and with technetium-99m using a peptide based natural chelating system at the C-terminus. 22, 23 Earlier it was shown that both labeling methods yielded residualising radiocatabolites and similar biodistribution profiles (kidney radioactivity uptake was 191±15%ID/g for 99m Tc and 168±24%ID/g for 111 In at 4 h p.i.). 22, 23 The aim of this study is to investigate the mechanism of renal reabsorption of anti-HER2 affibody molecules at the molecular level, and to determine the role of the megalin/cubilin receptor complex system in this process. counted manually using a cell counter (Scepter, Millipore, Billerica, US). Labeling of affibody molecules with indium-111 was performed as described previously. 22 Labeling with technetium99m was performed using a two-vial freeze-dried kit method as described previously. 29 After purification on the NAP-5 size-exclusion column (Amersham Biosciences, Uppsala, Sweden) purity of 99m Tc-Z HER2:2395 -C was >95 %, whereas the content of hydrolyzed 99m Tc did not exceed 1 %.
MATERIALS AND METHODS

Animal experiments
All animal experiments were planned and performed in accordance with national legislation on laboratory animals' protection. The studies had been approved by the Local Ethics Committee for Animal Research. In all in vivo experiments indium-labeled Z HER2:2395 -Cys was used.
To evaluate a gender influence of renal re-absorption of radiolabeled affibody molecules, four NMRI male and four NMRI female mice were iv injected with 1 µg of 111 In-labeled anti-HER2 affibody molecule (30 kBq). Biodistribution was determined at 4 h pi. Mice were exsanguinated by heart puncture under anesthesia, organs and tissue samples were collected, weighed and the radioactivity content was determined.
For SPECT imaging, five kidney-specific megalin deficient mice (30) and five wild-type mice were injected iv with 10 µg of 111 In-labeled anti-HER2 affibody molecule (20 MBq). SPECT images were acquired at 4 h pi, using the USPECT II (MILabs, Utrecht, The Netherlands). Mice were scanned in prone position under general anesthesia (isoflurane/N 2 O/O 2 ) for 45 min using the 1.0-mm diameter pinhole collimator tube. After completion of the acquisition of the images mice were euthanized and the concentration of the radioactivity in dissected tissues was determined as described above. Scans were reconstructed with MILabs reconstruction software, using an ordered-expectation maximization algorithm, with a voxel size of 0.375 mm.
Cell Experiments
Opossum kidney cell line (OK) and ovarian cancer cells (SKOV-3) were purchased from ATCC, via LGC Standards AB, Boras, Sweden. OK cells were cultured in MEM Earle's and SKOV-3 cells in RPMI medium complemented with 10% fetal calf serum (FCS), 2mM L-glutamine and PEST (penicillin 100 IU/ml, streptomycin 100 µg/ml), all from Biochrom AG, Berlin, Germany.
These media are referred to as complete media in the text. In all experiments with OK cells, cells were incubated in 1% FCS medium. Cells were detached using trypsinethylenediaminetetraacetic acid (EDTA) solution (0.25% trypsin, 0.02% EDTA in buffer;
Biochrom AG, Berlin, Germany). In vitro studies were performed in triplicate. In all cell experiments, 99m Tc-labeled affibody molecule Z HER2:2395 -Cys was used. Cells were seeded two days before the experiment in Petri dishes (ø 3.5 cm) in amount 2·10 6 cell/dish.
Binding kinetics: cell-associated radioactivity as a function of the incubation time
Cultured OK cells were washed once with serum-free medium and incubated with 1 mL of 1 nM 99m Tc -Z HER2:2395 -Cys in 1% FCS medium at 4°C up to 4 h. At pre-determined time points, the cells were washed two times with serum free-medium and treated with 0.5 ml/dish trypsin-EDTA at room temperature. When the cells were detached, 0.5 ml/dish serum-free medium was added and the cells were re-suspended and collected. The radioactivity was measured and percentage of cell-associated radioactivity at different time points was calculated. Data were normalized to maximum cell associated radioactivity. 
Binding
Receptor expression and affinity, Scatchard analysis
OK cells were incubated for 2 h at 4°C with 99m Tc -Z HER2:2395 -Cys (concentration range of 0.5 to 300 nM). For each data point, four dishes were used, including 1 pre-saturated with 30 µM unlabeled Z HER2:342 to determine un-specific binding. After incubation, medium was aspirated and the cells were treated as described above. From the cell suspension 0.1 ml was used for cell counting and the rest -for radioactivity measurements. Finally data were corrected on un-specific binding.
Cellular processing of 99m Tc -Z HER2:2395 -Cys by OK cells
OK cells were incubated with 3 or 30 nM 99m Tc -Z HER2:2395 -Cys in 1% FCS medium at 37°C (5% CO 2 ). At various time points, the medium was collected and the cells were washed once with serum-free medium. The membrane-bound and internalized radioactivity was estimated essentially as described by Wållberg. 31 Briefly, cells were treated with 0.5 ml 4 M urea solution in a 0.2 M glycine buffer, pH 2.5, for 5 min on ice. The acid supernatant was collected and the cells were washed twice with an additional 0.5 ml of acid buffer, which were also collected. The radioactivity in the acid fractions was considered as membrane bound radioactivity. For lysis, 0.5 ml of 1 M sodium hydroxide solution was added and the cells were incubated at 37˚C for at least 0.5 h. The alkaline solution containing cell debris was collected. Dishes were washed with an additional 0.5 ml basic solution and the basic fractions were pooled. The radioactivity in alkaline fractions was considered to contain the internalized activity.
Data analysis and statistics
Data for cell analysis were investigated by unpaired, two-tailed t test using GraphPad Prism (version 4.00 for Windows GraphPad Software, San Diego, California, USA) to find significant statistical difference (p<0.05). Binding data were analyzed using the GraphPad Prism software package.
RESULTS
Animal experiments
The biodistribution data of 111 In-labeled anti-HER2 affibody molecules are presented in Tables 1   and 2 . No apparent difference in radioactivity uptake in kidneys related to mice gender was found. Remarkably, uptake of 111 In-DOTA-Z HER2:2395 -Cys in the kidney of the megalin-deficient mice was identical to the uptake in the kidneys of the wild-type mice. Micro-SPECT images of kidney in megalin-deficient mice and wild type mice of 111 In-DOTA-Z HER2:2395 -Cys confirmed the identical accumulation of radioactivity in kidneys (Fig. 1) , indicating that megalin expression in the kidney is not essential for renal uptake of 111 In-labeled anti-HER2 affibody molecules.
In Vitro Characterization
The in vitro assay showed that 99m Tc -Z HER2:2395 -Cys at 4°C showed rapid binding to OK cells that reached a plateau almost in 1.5 h with cell associated radioactivity 3.6% from added ( Fig. 2) .
It was also found that incubation of cells at 4°C should not exceed four hours, since cells start to detach. Pre-incubation of OK cells in serum-free medium to stimulate protein transport did not influence binding of 99m Tc -Z HER2:2395 -Cys to OK cells (Fig. 3 ). Incubation at 4°C or addition of an excess of non-labeled affibody molecule significantly decreased binding.
The IC 50 values of the anti-HER2 affibody molecule Z HER2:342 , the non-HER2 affibody molecules Z EGFR , Z insuline , Z taq and albumin to OK cells were determined (see Fig. 4A and bound to the receptor with lower affinity), the cell-associated and internalized radioactivity increased continuously during the experiment (about 80% bound within first hour).
DISCUSSION
The mechanism of renal reabsorption and retention of radiolabelled peptides and small proteins has been studied by several groups during the last decade. Possible renal toxicity and tentative mechanisms of its prevention utilizing various blockers were the main driving forces for these studies. The majority of these studies was performed using in vivo models. In particular the molecular mechanism of kidney reabsorption of radiolabeled peptides and proteins mediated by megalin/cubilin co-receptors has attracted substantial attention during last years. Megalin and cubilin are synergistically acting endocytic receptors located mainly on the brush border of the apical parts of proximal tubules. 32 Megalin is a large transmembrane receptor; cubilin is a somewhat smaller receptor with no extracellular domain, which directs the trafficking of its ligands towards lysosomes through dimerization with megalin. Both receptors are important for the recovery of proteins such as albumin, vitamin binding proteins, hormones and apolipoproteins from the glomerular filtrate. Involvement of megalin in renal reabsorption of radiolabeled somatostatin analogues has been demonstrated. 8, 26 Later, it has been confirmed that the same receptor pair is partly responsible for renal reuptake of other peptides and proteins such as exendin, minigastrin and neurotensin. 11 Interestingly, although the level of expression of megalin/cubilin co-receptors in mice does not differ between the sexes, the same radiolabeled peptide exhibits higher renal uptake in female than in male mice. 11 Co-infusion of substances that are ligands of megalin/cubilin, such as positively charged amino acids and albumin fragments, reduce the kidney uptake of radiolabeled small protein. 9, 33, 34 Recently, involvement of megalin in renal reabsorption of radiolabeled anti-EGFR nanobodies (15 kDa) has been demonstrated, 35 despite EGFR expression in proximal tubule. 36 In summary, the studies so far suggest that the most important mechanism responsible for renal reabsorption of small radiolabeled proteins and peptides is megalin-mediated tubular reabsorption.
Affibody molecules appeared as promising imaging probes for in vivo detection of several tumor-associated molecular abnormalities. 16 Their prompt extravasation, high uptake by tumors, low uptake in normal tissues and rapid renal clearance provided high contrast images within a few hours after injection. 17 However, affibody molecules labeled with radiometals consistently
show high radioactivity accumulation in the kidneys. Although the kidneys are a well-defined structure, high uptake in the kidney might obscure imaging of lesions in the kidneys or in their vicinity and it might cause high radiation doses during therapeutic application. It is known that HER2 is expressed only in developing proximal tubules. 36 Moreover, it was found that high renal reabsorption occurs for anti-HER2 affibody molecules independent of the labeling method used, but in the case of non-residualizing labels (radiohalogens and some technetium-99m and rhenium-188) renal retention is low. 25, 37 At the same time tumor uptake and retention of radioactivity is stable for both residualizing radiometals and non-residualizing radiohalogens (see Fig. 7 ). Long retention of radioactivity in tumors correlates well with slow internalization rates of anti-HER2 affibody molecules in HER2-expressing tumor cells. 31, 38 This mismatch indicates that different processes are involved in cellular processing of radiolabeled affibody molecules in tumor cells and in kidneys. Knowledge about different chelators and the properties they confer to the targeting agent and optimization of labeling chemistry enabled reduction of renal retention of radioactivity. 19, 21, 24, 39, 40 However, the molecular mechanism of reabsorption of affibody molecules presumably by tubular cells is not fully understood.
In the present study, 111 In-labeled anti-HER2 affibody molecules were injected in NMRI mice:
the same level of the injected activity was retained in the kidneys in both male and female mice. would be substantial (about 50% of bound radioactivity). At this concentration, 4·K D1 or 0.3·K D2 , approximately 80% of high affinity receptors and 25% of low affinity receptors will be occupied.
At higher concentration (30 nM), the more abundant low affinity receptor should predominantly contribute to binding and cellular processing pattern of 99m Tc -Z HER2:2395 -Cys. We found that binding kinetics were very rapid for both receptors and internalization was slow. After 2 h incubation at the lower concentration, the cell-associated activity started to decline, and decreased to 60% of maximum value at 8 h of incubation. It should be noted that no depletion of radiolabeled affibody molecules occurred. Such a pattern points to internalization of the receptorligand complex without subsequent repopulation of the receptors. This pattern has not been observed for anti-HER2 affibody molecules bound to HER2 expressing cells. 21 In HER2
expressing tumor cells, monomeric affibody molecules do not trigger intracellular signaling, 41 which is reflected in slow internalization of a ligand-receptor complex. 21 The binding and processing pattern after binding to the low affinity receptor was different: after rapid binding during the first two hours, the cell-associated radioactivity increased slowly during the 8 h period. Taking into account that the high affinity receptor bound activity decreased, it can be assumed that the low affinity receptor is constantly repopulated. After 8 h internalized radioactivity was at a level that was 2-fold higher than that observed in HER2 expressing tumor cells. 21 We started this project with the aim to identify molecular mechanism of renal reabsorption of anti-HER2 affibody molecule Z HER2:2395 -Cys in particular and affibody molecules as scaffold protein in general. Development of efficient predictive in vitro models can help to reduce a number laboratory animals used for development of new imaging agents. We hypothesized that the mechanism of renal reabsorption for affibody molecules was similar to that of other small proteins, e.g. megalin/cubilin mediated. Unexpectedly, we have found that this co-receptor system is not involved in renal reabsorption of anti-HER2 affibody molecules. Moreover, in our in vitro model anti-HER2 affibody molecule binds to two types (or sub-types) of receptors with high affinity in low nanomolar range. The nature of these receptors on OK cells still needs to be identified.
In conclusion, we have shown that megalin/cubilin co-receptors do not play a significant role in renal uptake of radiolabeled anti-HER2 affibody molecules in mice. Experiments with opossum tubular OK cells indicated that binding of anti-HER2 affibody molecule 99m Tc -Z HER2:2395 -Cys is mediated by scavenger receptors cross-reacting with the binding site of the anti-HER2 affibody molecules, but it is unlikely that HER2 is one of them. We are considering approaches to further identify these receptor types. The results of this study indicate that affibody molecules and other scaffold-based targeting proteins with relatively low kidney uptake can be selected using in vitro studies with tubular kidney cells.
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